Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia : the MD Anderson experience

• Published in: Bone marrow transplantation (Basingstoke) Vol. 17; no. 5; pp. 775 - 779
• Main Authors: KHOURI, I. F, KANTARJIAN, H. M, TALPAZ, M, GIRALT, S, RIOS, M. O, HESTER, J. P, CHAMPLIN, R. E, DEISSEROTH, A. B
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.05.1996
• Subjects: Adolescent; Adult; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Biological and medical sciences; Combined Modality Therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Drug Tolerance; Female; Graft Survival; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Interferon-alpha - adverse effects; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - therapy; Leukemia, Myeloid, Chronic-Phase - drug therapy; Leukemia, Myeloid, Chronic-Phase - therapy; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Time Factors; Transplantation, Autologous; Antineoplastic agent; Human; Transfusion; Stem cell; Hematopoietic cell; Malignant hemopathy; Blood; Myeloproliferative syndrome; Autograft; Chemotherapy; Chronic; Follow up study; Chronic myelocytic leukemia; Bone marrow; Graft; Combined treatment; High dose

The purpose of this study was to evaluate the effectiveness of unpurged autologous stem cell transplantation (ASCT) for chronic myelogenous leukemia (CML) and its impact on the survival of patients in first and late chronic phase (CML-CP) including those resistant to or unable to tolerate interferon...